With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.

Commission backs purchasers and end payers in appeal of district court dismissal of suits against Forest and six generic manufacturers. It contends the court contravened Supreme Court’s Actavis decision and proffered its own justifications for side deals in patent settlements.

Commission backs purchasers and end payers in appeal of district court dismissal of suits against Forest and six generic manufacturers. It contends the court contravened Supreme Court’s Actavis decision and proffered its own justifications for side deals in patent settlements.

There are many new pressures on biopharmaceutical profitability but will Merck & Co’s attempt to reverse the drug pricing aspects of the Inflation Reduction Act just divert costs to patients?